← SynDRA
NALTREXONE
SynDRA canonical compound SYN0001078 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | OPRM1 |
|---|
| Mechanism of action | Opioid receptor antagonist |
|---|
| Indication | abstinence from alcohol |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- OPRD1
- OPRK1
- OPRM1
- CHRNA7
- CYP2D6
- Chrna4
- Oprd1
- Oprk1
- Oprm1
- SIGMAR1
- Sigmar1
Mechanisms of action (all sources)
- Opioid receptor antagonist
- OPRK1 ANTAGONIST
- Opioid receptors; mu/kappa/delta antagonist
- OPRD1 ANTAGONIST
- OPRM1 ANTAGONIST
Drug classes
- Opioid Antagonists
- Alcohol Deterrents
- Central Nervous System Agents
- Narcotic Antagonists
- Peripheral Nervous System Agents
- Sensory System Agents
- Opioid Antagonist
ATC classes
- N07B · DRUGS USED IN ADDICTIVE DISORDERS
- ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
- OPIOIDS
Cross-references
Synonyms
- cyclopropylmethylnoroxymorphone
- naltrel
- naltrexone hydrochloride
- naltrexone hydrochloride dihydrate
- naltrexone HCl
- Naltrexona
- EN-1639A FREE BASE
- EN-1639A [AS HYDROCHLORIDE]
- NSC-758439
- Celupan
- Trexal
- Vivitrol
- Depotrex
- Naltrel
- Vivitrex
- Naltrexone Depot
- IBS therapy, Pain Therapeutics
- Irritable bowel syndrome therapy, Pain Therapeutics
- PTI-901
- XR-NTX
- Naltrexone (sustained release), DAS
- Naltrexone (sustained release), elbion
- Naltrexone depot (injectable suspension), DrugAbuse Sciences
- Naltrexone depot (injectable suspension), elbion
- Opioid antagonists (irritable bowel syndrome), Pain Therapeutics
- Naltrexone (low-dose), Pain Therapeutics
- Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek
- Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma
- Naltrexone (once-monthly controlled-release, Medisorb), Alkermes
- ReVia
- N-Cyclopropylmethylnoroxymorphone
- Nemexin
- 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
- N-Cyclopropylmethyl-14-hydroxydihydromorphinone
- 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
- 5S6W795CQM
- CHEBI:7465
- NSC 758439
Reported adverse events
- Depression
- Increased appetite
- Nasal congestion
- Abdominal pain
- Anxiety
- Arthralgia
- Dizziness
- Headache
- Hypertension
- Insomnia
- Nausea
- Rash
Look up NALTREXONE in the interactive SynDRA portal →